Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 0.2% - Here's What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares were down 0.2% during mid-day trading on Thursday . The stock traded as low as $6.20 and last traded at $6.32. Approximately 957,386 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 5,717,877 shares. The stock had previously closed at $6.33.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the stock. Jefferies Financial Group decreased their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating for the company in a research report on Tuesday, September 3rd. KeyCorp lowered their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an "overweight" rating on the stock in a research report on Thursday, July 11th. Leerink Partners cut their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating for the company in a research report on Tuesday, September 3rd. Finally, Needham & Company LLC decreased their target price on Recursion Pharmaceuticals from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Wednesday, September 4th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Hold" and a consensus price target of $9.40.

Recursion Pharmaceuticals Stock Up 0.5 %

The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $6.73 and a two-hundred day simple moving average of $7.74. The company has a market cap of $1.79 billion, a PE ratio of -3.90 and a beta of 0.80.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.05). The business had revenue of $14.42 million for the quarter, compared to analyst estimates of $11.96 million. Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business's revenue was up 30.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.38) earnings per share. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.58 earnings per share for the current year.

Insider Activity

In other news, COO Tina Marriott sold 6,000 shares of Recursion Pharmaceuticals stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total transaction of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at $3,939,803.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $6.35, for a total value of $95,250.00. Following the sale, the chief financial officer now owns 1,340,968 shares in the company, valued at $8,515,146.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $7.56, for a total value of $45,360.00. Following the completion of the transaction, the chief operating officer now directly owns 521,138 shares in the company, valued at approximately $3,939,803.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 195,682 shares of company stock worth $1,284,153 over the last ninety days. Corporate insiders own 15.75% of the company's stock.

Institutional Trading of Recursion Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. boosted its stake in Recursion Pharmaceuticals by 1,173.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 87,539 shares of the company's stock worth $611,000 after buying an additional 80,664 shares during the period. Brighton Jones LLC acquired a new stake in shares of Recursion Pharmaceuticals in the third quarter valued at $89,000. International Assets Investment Management LLC grew its stake in shares of Recursion Pharmaceuticals by 527.3% in the third quarter. International Assets Investment Management LLC now owns 84,682 shares of the company's stock valued at $558,000 after buying an additional 71,182 shares in the last quarter. Private Advisor Group LLC raised its holdings in shares of Recursion Pharmaceuticals by 28.6% in the 3rd quarter. Private Advisor Group LLC now owns 15,419 shares of the company's stock valued at $102,000 after buying an additional 3,432 shares during the period. Finally, Foundations Investment Advisors LLC lifted its stake in Recursion Pharmaceuticals by 25.0% during the 3rd quarter. Foundations Investment Advisors LLC now owns 193,036 shares of the company's stock worth $1,272,000 after acquiring an additional 38,642 shares in the last quarter. 89.06% of the stock is currently owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.